Neurocrine axes Parkinson's collab with Voyager after safety issues, jeopardizing biotech's long-running centerpiece
Six years ago, Third Rock Ventures launched Voyager Therapeutics with $45 million and a goal of bringing gene therapy into some of the most notorious neurological diseases, most notably Parkinson’s. Now that program, long their lead and only clinical asset, is in jeopardy.
Voyager announced Tuesday afternoon that Neurocrine Biosciences has terminated their agreement to co-develop the Parkinson’s gene therapy after safety issues put the program on hold last year. Voyager said they are still evaluating whether or not to continue developing the gene therapy internally. They pinned Neurocrine’s decision on a “portfolio review and prioritization of its current pipeline assets.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.